Invitation to U.S. Food & Drug Administration ME/CFS Teleconference with Patient Advocates and Organizations - September 13, 2012

[Guest guest]

From: Abercrombie, Ann (HHS/OASH)

>

FW: Invitation to U.S. Food & Drug

Administration ME/CFS Teleconference

with Patient Advocates and

Organizations - September 13, 2012

See below.

This message is being sent out to the CFSAC

listserv at the request of the FDA.

Please do not reply to this message. Direct all

questions regarding the teleconference to the FDA

(see below.)

The CFSAC support team cannot answer questions

concerning this FDA teleconference.

The CFSAC Support Team

http://www.hhs.gov/advcomcfs/index.html

Sign up for the CFSAC listserv to receive the latest

updates about CFSAC:

http://www.hhs.gov/advcomcfs/cfsac_email_list.html

````````

From: Cirincione, Dominic

Sent: Friday, August 17, 2012 10:16 AM

To: Cirincione, Dominic (FDA/OC); , Randi

(FDA/CDER)

Subject: Invitation to U.S. Food & Drug

Administration ME/CFS Teleconference with

Patient Advocates and Organizations -

September 13, 2012

August 17, 2012

Dear Colleagues:

The U.S. Food & Drug Administration (FDA) is

pleased to invite you to a stakeholder

teleconference between FDA and Myalgic

Encephalomyelitis/Chronic Fatigue Syndrome

(ME/CFS) patients and advocacy organizations on

September 13, 2012. Dr. Janet Woodcock, Director

of the Center of Drug Evaluation and Research, will

lead the call.

The purpose of the call is to discuss issues of

mutual interest and concern including the lack of

approved treatment options available for ME/CFS

and how treatment development might be

facilitated.

The teleconference is scheduled for Thursday,

September 13, 2012 from 10:00 am – 11:30 am.

Registration is required and must be received by

September 7, 2012.

Early registration is recommended because

telephone lines will be limited to the first 50 groups

and/or individuals who register. FDA may limit the

number of participants from each organization, as

well as the total number of participants, based on

current space limitations.

If you would like to participate, please send your

name, email address, telephone number and

affiliation information to Randi

(randi.clark@...) by no later than

September 7. Registrants will receive confirmation

and additional information about the teleconference

once registration has been received and accepted.

FDA looks forward to your participation.

Thank you,

Dominic Cirincione

dominic.cirincione@...